Nkarta Past Earnings Performance
Past criteria checks 0/6
Nkarta's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 113.4% per year.
Key information
-17.0%
Earnings growth rate
59.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -113.4% |
| Return on equity | -25.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
Oct 31We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Sep 10
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Aug 14Nkarta: A Look Into Q1 Results And Upcoming Catalysts
May 23Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Apr 27Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10Nkarta gets greenlight from the FDA for NKX019 cancer study
Apr 28We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25
Revenue & Expenses Breakdown
How Nkarta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -111 | 30 | 97 |
| 30 Jun 24 | 0 | -108 | 29 | 94 |
| 31 Mar 24 | 0 | -116 | 29 | 96 |
| 31 Dec 23 | 0 | -118 | 30 | 97 |
| 30 Sep 23 | 0 | -122 | 31 | 100 |
| 30 Jun 23 | 0 | -125 | 31 | 102 |
| 31 Mar 23 | 0 | -119 | 30 | 97 |
| 31 Dec 22 | 0 | -114 | 28 | 91 |
| 30 Sep 22 | 0 | -104 | 26 | 81 |
| 30 Jun 22 | 0 | -98 | 24 | 75 |
| 31 Mar 22 | 0 | -93 | 24 | 69 |
| 31 Dec 21 | 0 | -86 | 23 | 63 |
| 30 Sep 21 | 0 | -81 | 24 | 57 |
| 30 Jun 21 | 0 | -72 | 22 | 66 |
| 31 Mar 21 | 0 | -102 | 19 | 42 |
| 31 Dec 20 | 0 | -91 | 15 | 36 |
| 30 Sep 20 | 0 | -84 | 11 | 25 |
| 30 Jun 20 | 0 | -73 | 8 | 0 |
| 31 Mar 20 | 0 | -27 | 6 | 7 |
| 31 Dec 19 | 0 | -21 | 5 | 0 |
| 31 Dec 18 | 7 | 0 | 3 | 0 |
Quality Earnings: NKTX is currently unprofitable.
Growing Profit Margin: NKTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NKTX is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare NKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NKTX has a negative Return on Equity (-25.67%), as it is currently unprofitable.